Richard Payne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Richard Payne has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
Akosua N. Tuffuor
The Divinity School, Duke University, Durham, North Carolina, USA
1 shared publication
Latest Publications
- 1 September 2017
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 54 (3) , 400-403
Isolation and Suffering Related to Serious and Terminal Illness: Metaphors and Lessons From Albert Camus' Novel, The Plague
- 1 September 2017
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 54 (3) , 400-403
Isolation and Suffering Related to Serious and Terminal Illness: Metaphors and Lessons From Albert Camus' Novel, The Plague
- 1 February 2016
- Published by SAGE Publications in Journal of Palliative Medicine
- Vol. 19 (2) , 131-133
Racially Associated Disparities in Hospice and Palliative Care Access: Acknowledging the Facts While Addressing the Opportunities to Improve
- 1 February 2016
- Published by SAGE Publications in Journal of Palliative Medicine
- Vol. 19 (2) , 131-133
Racially Associated Disparities in Hospice and Palliative Care Access: Acknowledging the Facts While Addressing the Opportunities to Improve
- 1 May 2015
- Published by Elsevier in Clinics in Geriatric Medicine
- Vol. 31 (2) , 271-279
Culturally Relevant Palliative Care
- 1 May 2015
- Published by Elsevier in Clinics in Geriatric Medicine
- Vol. 31 (2) , 271-279
Culturally Relevant Palliative Care
- 1 January 2007
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 8 (suppl 1) , S3-S7
Recognition and Diagnosis of Breakthrough Pain
To review major clinical issues related to recognition and diagnosis of breakthrough pain. Persistent pain and breakthrough pain (BTP) are distinct clinical entities that should be recognized, diagnosed, and treated individually. BTP is common in patients with cancer and a variety of other chronic diseases. Reported incidence of BTP varies widely from 16% to 95% of those with persistent pain syndromes. Such variability is likely due to lack of a clear consensus on the definition of BTP. It is most commonly defined as an abrupt, short-lived, and intense pain that "breaks through" the around-the-clock analgesia that controls persistent pain. The three subtypes of BTP are incident, idiopathic, and end-of-dose failure. BTP also is categorized as somatic, visceral, neuropathic, or mixed. Appropriate assessment of the patient takes into consideration source, severity, pattern, subtype, and cause of pain. Successful treatment is important because BTP has a profound impact on the patient's quality of life, as well as cost of health care. BTP is likely to be underdiagnosed and undertreated because of the lack of consensus on its definition and unwarranted concerns among health care professionals and patients about overmedicating. Additionally, and for reasons not entirely clear, many physicians and other health care providers place a low priority on pain management and underrecognize the occurrence of BTP in patients with persistent pain. Greater knowledge and awareness of BTP in cancer and nonmalignant conditions will lead to improved recognition and diagnosis of BTP and ultimately to more effective treatment and enhanced quality of life for these patients.
- 1 January 2007
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 8 (suppl 1) , S3-S7
Recognition and Diagnosis of Breakthrough Pain
To review major clinical issues related to recognition and diagnosis of breakthrough pain. Persistent pain and breakthrough pain (BTP) are distinct clinical entities that should be recognized, diagnosed, and treated individually. BTP is common in patients with cancer and a variety of other chronic diseases. Reported incidence of BTP varies widely from 16% to 95% of those with persistent pain syndromes. Such variability is likely due to lack of a clear consensus on the definition of BTP. It is most commonly defined as an abrupt, short-lived, and intense pain that "breaks through" the around-the-clock analgesia that controls persistent pain. The three subtypes of BTP are incident, idiopathic, and end-of-dose failure. BTP also is categorized as somatic, visceral, neuropathic, or mixed. Appropriate assessment of the patient takes into consideration source, severity, pattern, subtype, and cause of pain. Successful treatment is important because BTP has a profound impact on the patient's quality of life, as well as cost of health care. BTP is likely to be underdiagnosed and undertreated because of the lack of consensus on its definition and unwarranted concerns among health care professionals and patients about overmedicating. Additionally, and for reasons not entirely clear, many physicians and other health care providers place a low priority on pain management and underrecognize the occurrence of BTP in patients with persistent pain. Greater knowledge and awareness of BTP in cancer and nonmalignant conditions will lead to improved recognition and diagnosis of BTP and ultimately to more effective treatment and enhanced quality of life for these patients.
- Open Access
- 1 January 2007
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 8 (suppl 1) , S1-S2
Introduction: The Scope of Breakthrough Pain in Clinical Practice
- 1 January 2007
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 8 (suppl 1) , S1-S2
Open AccessIntroduction: The Scope of Breakthrough Pain in Clinical Practice